Spots Global Cancer Trial Database for dostarlimab
Every month we try and update this database with for dostarlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | NCT06256588 | Neoplasms, Head... | Dostarlimab Placebo | 18 Years - | GlaxoSmithKline | |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | NCT05065021 | Ovarian Cancer Fallopian Tube ... Primary Periton... High Grade Sero... High Grade Endo... | Niraparib Dostarlimab Bevacizumab Paclitaxel | 18 Years - | University Health Network, Toronto | |
| Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | NCT05819892 | Endometrial Can... | Paclitaxel Carboplatin Dostarlimab Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | NCT06317311 | Carcinoma | Dostarlimab Carboplatin Paclitaxel | 18 Years - | GlaxoSmithKline | |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | NCT03739710 | Neoplasms | Docetaxel Feladilimab Ipilimumab GSK4428859A Dostarlimab GSK6097608 | 18 Years - | GlaxoSmithKline | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | NCT04837209 | Breast Cancer Triple Negative... | Niraparib Dostarlimab Radiation thera... | 18 Years - | Massachusetts General Hospital | |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | NCT04165772 | Rectal Adenocar... Clinical Stage:... Stage III (Any ... Solid Tumor Solid Tumor, Ad... | TSR-042 or Dost... capecitabine or... Intensity Modul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy | NCT04655976 | Lung Cancer, No... | Cobolimab Dostarlimab Docetaxel | 18 Years - | GlaxoSmithKline | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | NCT04673448 | Anatomic Stage ... Anatomic Stage ... BRCA-Associated... BRCA-Associated... Metastatic BRCA... Metastatic Brea... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Prim... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Br... Unresectable Fa... Unresectable Ma... Unresectable Ov... Unresectable Pa... Unresectable Pr... | Dostarlimab Niraparib | 18 Years - | University of Washington | |
| Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | NCT04493060 | Metastatic Panc... Stage IV Pancre... | Dostarlimab Niraparib | 18 Years - | Mayo Clinic | |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | NCT05526989 | Penile Carcinom... | Dostarlimab Niraparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | NCT04895046 | HRD Cholangiocarcin... Metastatic Canc... | Niraparib Dostarlimab Dostarlimab | 18 Years - | Hoosier Cancer Research Network | |
| Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | NCT06059495 | Adenocarcinoma ... Gastric Adenoca... | Dostarlimab | 18 Years - 75 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | NCT05700721 | Brain Metastase... | Niraparib Dostarlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | NCT02715284 | Neoplasms | Dostarlimab | 18 Years - | Tesaro, Inc. | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | NCT05819892 | Endometrial Can... | Paclitaxel Carboplatin Dostarlimab Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer | NCT03955471 | Ovarian Neoplas... | Niraparib Dostarlimab | 18 Years - | Tesaro, Inc. | |
| Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | NCT05870761 | Recurrent Endom... | Biospecimen Col... Computed Tomogr... Dostarlimab Magnetic Resona... Niraparib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | NCT05565378 | Lung Cancer, No... | Pembrolizumab Dostarlimab Belrestotug GSK6097608 | 18 Years - | GlaxoSmithKline | |
| Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC | NCT04313504 | Head and Neck C... | Niraparib Dostarlimab | 18 Years - | University of Cincinnati | |
| Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | NCT04446351 | Neoplasms | GSK6097608 Dostarlimab Cobolimab Belrestotug | 18 Years - | GlaxoSmithKline | |
| Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT06062420 | Neoplasms, Head... | Dostarlimab Belrestotug GSK6097608 | 18 Years - | GlaxoSmithKline | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer | NCT04068753 | Recurrent Cervi... Progressive Cer... | Niraparib dostarlimab | 18 Years - | University of Oklahoma | |
| A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | NCT04926324 | Rectal Neoplasm... Rectal Neoplasm... | Niraparib Dostarlimab Short course ra... | 18 Years - | University of Iowa | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | NCT06023862 | Ovarian Neoplas... Endometrial Neo... Uterine Cervica... Vulvar Cancer Vagina Neoplasm Clear Cell Carc... | Dostarlimab Bevacizumab Doxorubicin Gemcitabine Paclitaxel Pegylated lipos... | 18 Years - | Yonsei University | |
| Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | NCT03308942 | Neoplasms | Niraparib Pembrolizumab TSR-042 (Dostar... | 18 Years - | Tesaro, Inc. | |
| PREventing Second Cancers With DOSTARlimab | NCT05855811 | Recurrent Cance... Primary Cancer Second Cancer | Dostarlimab | 18 Years - | Centre Leon Berard | |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | NCT05277051 | Neoplasms | GSK4381562 Dostarlimab GSK4428859A | 18 Years - | GlaxoSmithKline | |
| Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | NCT04701307 | Lung Small Cell... Neuroendocrine ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... | Dostarlimab Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | NCT04165772 | Rectal Adenocar... Clinical Stage:... Stage III (Any ... Solid Tumor Solid Tumor, Ad... | TSR-042 or Dost... capecitabine or... Intensity Modul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab | NCT04779151 | Urothelial Blad... Gastric Adenoca... Gastro-oesophag... Head and Neck C... Biliary Tract C... Platinum-sensit... Clear Cell Rena... Pancreatic Duct... | Dostarlimab Niraparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT04581824 | Lung Cancer, No... | Dostarlimab Pembrolizumab Chemotherapy | 18 Years - | GlaxoSmithKline | |
| Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | NCT05126342 | Recurrent Ovari... Recurrent Fallo... Primary Periton... | Niraparib Dostarlimab | 18 Years - | AGO Research GmbH | |
| A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | NCT03843359 | Neoplasms | GSK3745417 Dostarlimab | 18 Years - | GlaxoSmithKline | |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | NCT06317311 | Carcinoma | Dostarlimab Carboplatin Paclitaxel | 18 Years - | GlaxoSmithKline | |
| Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | NCT05870761 | Recurrent Endom... | Biospecimen Col... Computed Tomogr... Dostarlimab Magnetic Resona... Niraparib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | NCT06405230 | Lung Cancer, No... | Pembrolizumab Dostarlimab Pemetrexed+ (ca... | 30 Years - | GlaxoSmithKline | |
| PREventing Second Cancers With DOSTARlimab | NCT05855811 | Recurrent Cance... Primary Cancer Second Cancer | Dostarlimab | 18 Years - | Centre Leon Berard | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC | NCT04313504 | Head and Neck C... | Niraparib Dostarlimab | 18 Years - | University of Cincinnati | |
| Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT06062420 | Neoplasms, Head... | Dostarlimab Belrestotug GSK6097608 | 18 Years - | GlaxoSmithKline | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | NCT05201547 | Endometrial Can... | Carboplatin-Pac... Dostarlimab | 18 Years - | ARCAGY/ GINECO GROUP | |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | NCT03739710 | Neoplasms | Docetaxel Feladilimab Ipilimumab GSK4428859A Dostarlimab GSK6097608 | 18 Years - | GlaxoSmithKline | |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | NCT04165772 | Rectal Adenocar... Clinical Stage:... Stage III (Any ... Solid Tumor Solid Tumor, Ad... | TSR-042 or Dost... capecitabine or... Intensity Modul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | NCT05526989 | Penile Carcinom... | Dostarlimab Niraparib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 | NCT06065462 | Ovarian Clear C... | Dostarlimab LB-100 | 18 Years - | M.D. Anderson Cancer Center | |
| Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | NCT05060432 | Advanced Cancer Lung Cancer Head and Neck C... Melanoma | EOS-448 pembrolizumab inupadenant Dostarlimab SOC chemotherap... | 18 Years - | iTeos Therapeutics | |
| Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | NCT06059495 | Adenocarcinoma ... Gastric Adenoca... | Dostarlimab | 18 Years - 75 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | NCT05405192 | Gestational Tro... | Dostarlimab | 18 Years - | University of Miami | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers | NCT05239546 | Colon Cancer dMMR Colorectal... | Dostarlimab | 18 Years - | University of Iowa |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
